

George Pouligiannis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2648260/publications.pdf>

Version: 2024-02-01

45
papers

6,470
citations

159525

30
h-index

243529

44
g-index

48
all docs

48
docs citations

48
times ranked

12955
citing authors

#	ARTICLE	IF	CITATIONS
1	Banking on metabolomics for novel therapies in TNBC. <i>Cell Research</i> , 2022, 32, 423-424.	5.7	2
2	Reprogramming of fatty acid metabolism in cancer. <i>British Journal of Cancer</i> , 2020, 122, 4-22.	2.9	810
3	Universal Sample Preparation Unlocking Multimodal Molecular Tissue Imaging. <i>Analytical Chemistry</i> , 2020, 92, 11080-11088.	3.2	64
4	Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. <i>Cell</i> , 2020, 181, 1596-1611.e27.	13.5	77
5	Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. <i>Nature Communications</i> , 2019, 10, 2698.	5.8	75
6	Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence. <i>British Journal of Anaesthesia</i> , 2019, 123, e412-e423.	1.5	39
7	Asparagine bioavailability governs metastasis in a model of breast cancer. <i>Nature</i> , 2018, 554, 378-381.	13.7	362
8	Perioperative events influence cancer recurrence risk after surgery. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 205-218.	12.5	339
9	DNA Damage, Repair, and Cancer Metabolism. <i>Frontiers in Oncology</i> , 2018, 8, 15.	1.3	169
10	Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 160.	1.3	283
11	<i>PARK2</i> loss promotes cancer progression via redox-mediated inactivation of PTEN. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1329692.	0.3	26
12	<i>PARK2</i> Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. <i>Molecular Cell</i> , 2017, 65, 999-1013.e7.	4.5	103
13	Discovery of naturally occurring <i>ESR1</i> mutations in breast cancer cell lines modelling endocrine resistance. <i>Nature Communications</i> , 2017, 8, 1865.	5.8	108
14	Proteomics profiling of interactome dynamics by colocalisation analysis (COLA). <i>Molecular BioSystems</i> , 2017, 13, 92-105.	2.9	11
15	Deconstructing the Metabolic Networks of Oncogenic Signaling Using Targeted Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). <i>Methods in Molecular Biology</i> , 2017, 1636, 405-414.	0.4	1
16	Decreased function of survival motor neuron protein impairs endocytic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E4377-86.	3.3	45
17	Oncogenic <i>KRAS</i> Regulates Tumor Cell Signaling via Stromal Reciprocation. <i>Cell</i> , 2016, 165, 910-920.	13.5	267
18	Abstract A34: Oncogenic <i>KRAS</i> regulates pancreatic cancer cell signaling via stromal reciprocation. , 2016, , .		1

#	ARTICLE	IF	CITATIONS
19	Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. <i>Oncotarget</i> , 2015, 6, 10548-10562.	0.8	26
20	Wild-type <i>Kras</i> has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation. <i>International Journal of Experimental Pathology</i> , 2014, 95, 8-15.	0.6	9
21	Abstract NG05: Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53 null tumors. , 2014, , .		0
22	Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors. <i>Cell</i> , 2013, 155, 844-857.	13.5	173
23	Metabolic Stress Controls mTORC1 Lysosomal Localization and Dimerization by Regulating the TTT-RUVBL1/2 Complex. <i>Molecular Cell</i> , 2013, 49, 172-185.	4.5	183
24	The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4. <i>Cell</i> , 2013, 153, 840-854.	13.5	505
25	<i>IRS2</i> is a candidate driver oncogene on 13q34 in colorectal cancer. <i>International Journal of Experimental Pathology</i> , 2013, 94, 203-211.	0.6	49
26	Identification of CDCP1 as a hypoxia-inducible factor 2 \pm (HIF-2 \pm) target gene that is associated with survival in clear cell renal cell carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3483-3488.	3.3	57
27	The PI3K Pathway in Colorectal Cancers. , 2013, , 157-199.		1
28	Abstract 4588: Identification of CDCP1 as a HIF-2 \pm target gene involved in the regulation of cancer cell migration and metastasis.. , 2013, , .		0
29	Nuclear receptor binding protein 1 regulates intestinal progenitor cell homeostasis and tumour formation. <i>EMBO Journal</i> , 2012, 31, 2486-2497.	3.5	40
30	The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility. <i>Oncogene</i> , 2012, 31, 653-663.	2.6	28
31	Loss of <i>Rassf1a</i> Synergizes with Deregulated Runx2 Signaling in Tumorigenesis. <i>Cancer Research</i> , 2012, 72, 3817-3827.	0.4	45
32	RAS signalling in the colorectum in health and disease. <i>Cell Communication and Adhesion</i> , 2012, 19, 1-9.	1.0	21
33	Increased tumorigenesis associated with loss of the tumor suppressor gene <i>Cadm1</i> . <i>Molecular Cancer</i> , 2012, 11, 29.	7.9	33
34	Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses. <i>Science</i> , 2011, 334, 1278-1283.	6.0	984
35	Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling. <i>Science</i> , 2011, 332, 1322-1326.	6.0	772
36	Synergism between K-rasVal12 and mutant Apc accelerates murine large intestinal tumourigenesis. <i>Oncology Reports</i> , 2011, 26, 125-33.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Mutant Kâ€‹ <i>ras</i> promotes carcinogenâ€‹induced murine colorectal tumourigenesis, but does not alter tumour chromosome stability. <i>Journal of Pathology</i> , 2011, 223, 390-399.	2.1	12
38	Prognostic relevance of DNA copy number changes in colorectal cancer. <i>Journal of Pathology</i> , 2010, 220, 338-347.	2.1	48
39	Kâ€‹ <i>ras</i> exon 4A has a tumour suppressor effect on carcinogenâ€‹induced murine colonic adenoma formation. <i>Journal of Pathology</i> , 2010, 220, 542-550.	2.1	27
40	DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. <i>Histopathology</i> , 2010, 56, 167-179.	1.6	198
41	<i>PARK2</i> deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in <i>Apc</i> mutant mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15145-15150.	3.3	202
42	A constitutively activated form of the p110Î² isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11002-11007.	3.3	57
43	Mutated Kâ€‹ <i>ras</i> ^{<i>Asp12</i>} promotes tumourigenesis in <i>Apc</i> ^{<i>Min</i>} mice more in the large than the small intestines, with synergistic effects between Kâ€‹ <i>ras</i> and <i>Wnt</i> pathways. <i>International Journal of Experimental Pathology</i> , 2009, 90, 558-574.	0.6	59
44	p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours. <i>British Journal of Cancer</i> , 2008, 99, 1144-1152.	2.9	15
45	Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice. <i>Oncogene</i> , 2007, 26, 4415-4427.	2.6	38